Lineage Cell Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest
Lineage Cell Therapeutics, Inc. (LCTX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest of $33.07 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-16.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest · last filed 2017-03-16
- Lineage Cell Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2016-12-31 was -$5.12M.
- Lineage Cell Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2016-09-30 was $31.01M.
- Lineage Cell Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2016-06-30 was $24.11M.
- Lineage Cell Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for the quarter ending 2016-03-31 was -$16.92M.
- Lineage Cell Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2016 was $33.07M.
- Lineage Cell Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2015 was -$47.83M.
- Lineage Cell Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2014 was -$36.38M.
- Lineage Cell Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to noncontrolling interest for fiscal 2013 was -$43.76M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 12 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|
| 2016-12-31 | -$5.12M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $25.89M derived: sum of 2 quarters · filed 2017-03-16 | $49.99M derived: sum of 3 quarters · filed 2017-03-16 | $33.07M 10-K · filed 2017-03-16 | |
| 2016-09-30 | $31.01M 10-Q · filed 2016-11-04 | $55.12M derived: sum of 2 quarters · filed 2016-11-04 | $38.19M 10-Q · filed 2016-11-04 | $24.62M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2016-06-30 | $24.11M 10-Q · filed 2016-08-09 | $7.17M 10-Q · filed 2016-08-09 | -$6.39M derived: sum of 3 quarters · filed 2017-03-16 | -$20.34M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2016-03-31 | -$16.92M derived: 10-K 12 month − 3 quarters · filed 2017-03-16 | -$30.50M derived: sum of 2 quarters · filed 2017-03-16 | -$44.44M derived: sum of 3 quarters · filed 2017-03-16 | -$54.50M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-12-31 | -$13.57M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$27.52M derived: sum of 2 quarters · filed 2017-03-16 | -$37.58M derived: sum of 3 quarters · filed 2017-03-16 | -$47.83M 10-K · filed 2017-03-16 | |
| 2015-09-30 | -$13.95M 10-Q · filed 2016-11-04 | -$24.00M derived: sum of 2 quarters · filed 2016-11-04 | -$34.26M 10-Q · filed 2016-11-04 | -$44.52M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-06-30 | -$10.06M 10-Q · filed 2016-08-09 | -$20.23M 10-Q · filed 2016-08-09 | -$30.57M derived: sum of 3 quarters · filed 2017-03-16 | -$38.94M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-03-31 | -$10.22M 10-Q · filed 2015-05-08 | -$20.51M derived: sum of 2 quarters · filed 2017-03-16 | -$28.88M derived: sum of 3 quarters · filed 2017-03-16 | -$38.48M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2014-12-31 | -$10.29M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$18.66M derived: sum of 2 quarters · filed 2017-03-16 | -$28.26M derived: sum of 3 quarters · filed 2017-03-16 | -$36.38M 10-K · filed 2017-03-16 | -$36.38M 10-K · filed 2015-03-11 |
| 2014-09-30 | -$8.37M 10-Q · filed 2015-11-09 | -$17.96M derived: sum of 2 quarters · filed 2015-11-09 | -$26.08M 10-Q · filed 2015-11-09 | ||
| 2014-06-30 | -$9.59M 10-Q · filed 2015-08-10 | -$17.79M 10-Q · filed 2015-08-10 | |||
| 2014-03-31 | -$8.21M 10-Q · filed 2015-05-08 | ||||
| 2013-12-31 | -$43.76M 10-K · filed 2016-03-15 | -$43.76M 10-K · filed 2015-03-11 | |||
| 2012-12-31 | -$21.36M 10-K · filed 2015-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |